Viewing Study NCT00216632

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:55 PM
Ignite Modification Date: 2026-01-22 @ 12:24 PM
Study NCT ID: NCT00216632
Status: COMPLETED
Last Update Posted: 2012-12-07
First Post: 2005-09-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
Sponsor: Janssen Pharmaceutica N.V., Belgium
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Schizophrenia View
None Psychotic Disorders View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Schizophrenia, Schizoaffective disorder View
None antipsychotic agents View
None long-acting risperidone View
None intramuscular injection View